Unraveling the Role of MUC16 in Ovarian Cancer

MUC16, also known as CA125, is one of the most important mucin-related biomarkers in ovarian cancer research. As a large transmembrane glycoprotein expressed on epithelial surfaces and frequently elevated in ovarian malignancies, MUC16 connects tumor biology, diagnostic monitoring, therapeutic targeting, and emerging immunotherapy strategies.

Abstract

MUC16, commonly known as CA125, is a high-molecular-weight transmembrane mucin widely studied in ovarian cancer. It is expressed on epithelial cell surfaces and is present in multiple mucosal tissues, including the respiratory, digestive, reproductive, and ocular systems. In ovarian cancer, MUC16 is clinically significant because its shed extracellular component can be detected in serum and other body fluids, supporting its long-standing use as a tumor-associated biomarker. Beyond diagnosis and monitoring, MUC16 is increasingly being investigated as a therapeutic target for antibody-based therapies, CAR-T cell strategies, and combination treatment approaches. Understanding its structure, physiological function, and signaling activity is essential for advancing ovarian cancer research.

What is MUC16?

MUC16, commonly referred to as CA125, is a vital adhesion protein belonging to the extensive adhesion molecule family. This protein encodes a substantial glycoprotein comprising more than 20,000 amino acid residues. It is primarily found on the surface of human epithelial cells and is present in various mucosal regions, including the eyes, respiratory tract, digestive tract, and reproductive tract.

The Structure of MUC16

MUC16 is the largest transmembrane mucin, consisting of approximately 14,000 amino acids, with molecular weights ranging from 1.5 to 5 MDa. Structurally, it contains three major domains: an N-terminal domain, a tandem repeat domain, and a C-terminal domain.

N-Terminal Domain

The N-terminal domain of MUC16 contains multiple serine-rich regions embedded within a threonine-rich region spanning approximately 12,000 amino acids. These regions are exclusively O-glycosylated and contribute to the extensive glycoprotein character of MUC16.

Tandem Repeat Domain

The tandem repeat domain contains 12 to 60 repeats of 156 amino acids. These repeats are interspersed with SEA domains that contain both O-linked and N-linked glycosylation sites [1]. MUC16 contains 16 SEA modules, a feature that distinguishes it from MUC1 [2].

C-Terminal Domain

The C-terminal domain includes an extracellular domain, a short transmembrane region, and a 32-amino acid cytoplasmic domain. Within the cytoplasmic domain lies a polybasic amino acid motif, RRRKK, which binds ezrin/radixin/moesin, also known as ERM, actin-binding proteins [3]. This region also contains several serine, threonine, and tyrosine residues. The third tyrosine residue can be phosphorylated by c-Src kinase [4].

Fig. 1. Schematic of MUC16 structure [5].

Physiological Functions of CA125

CA125, an epitope located on the MUC16 molecule, plays multiple physiological roles in the human body. It is not confined to a single tissue or fluid; instead, it is distributed across several epithelial and mucosal environments, reflecting the broad biological relevance of MUC16.

CA125 is naturally present in cervical mucus, where it is primarily produced and released by endocervical cells in healthy women [6]. It is also abundant in amniotic fluid and the chorionic membrane of developing fetuses and is expressed in human milk [7]. Beyond these sites, CA125 can be detected in epithelial cells of the airways, respiratory glands, bronchial mucus, and other tissues, including the endocervix, endometrium, pleura, pericardium, secretory mammary glands, apocrine sweat glands, intestines, lungs, and kidneys.

CA125 is found during the embryonic development of ovaries but diminishes as development progresses. It can re-emerge in ovarian neoplasms [8]. Elevated CA125 levels may also be observed in peritoneal and pleural epithelial fluids and ascites because of its production by tissues derived from coelomic epithelium [9].

Researchers have explored therapeutic strategies targeting MUC16, particularly its tandem repeat domains, which are suspected locations of CA125 epitopes. Antibodies have been developed to target these domains with the goal of reducing ovarian cancer recurrence risk [10]. Examples of MUC16-targeted immunotherapeutic approaches include oregovomab and abagovomab, both designed as antibodies against MUC16 [11].

The Application and Prospects of Targeting MUC16 in Tumor Treatment

The potential applications of targeting MUC16 in tumor treatment are significant, especially in cancers characterized by MUC16 overexpression, such as ovarian cancer. Its unique expression pattern makes it a valuable marker for ovarian cancer and creates opportunities for improved early diagnosis, screening, and therapeutic intervention.

Diagnostic and Screening Applications

Researchers are developing specific molecular probes and biosensors to improve the accuracy of MUC16-associated cancer detection. These technologies may help clinicians identify tumors earlier and support more timely treatment decisions.

Antibody-Based Targeted Therapy

MUC16’s high expression specificity has encouraged the development of drugs and immunotherapies designed to target MUC16-positive tumor cells. Anti-MUC16 monoclonal antibodies may disrupt cancer cell growth signals, induce apoptosis, or activate immune-mediated tumor cell clearance. This targeted treatment strategy may improve tumor specificity while reducing unwanted effects on healthy cells.

CAR-T Cell Therapy

Researchers are also using MUC16 antigen specificity to develop CAR-T cell therapies. In this personalized strategy, a patient’s T cells are engineered to recognize and attack MUC16-positive tumor cells. Experimental studies have shown promising efficacy, offering a potential treatment direction for patients with advanced cancer.

Combination Treatment Strategies

MUC16-targeted therapy may also be combined with radiation therapy, chemotherapy, or immunotherapy. Such combination strategies may enhance treatment efficacy, reduce drug resistance, and provide more comprehensive tumor treatment options.

Signaling Pathway of MUC16

MUC16 is an adhesion-associated mucin involved in multiple cancer-related processes. Its overexpression has been reported in several tumor types, where it may contribute to cell adhesion, invasion, migration, proliferation, and survival through interactions with extracellular matrix components and oncogenic signaling pathways.

Ovarian Cancer

MUC16 is overexpressed in ovarian cancer and is associated with tumor development, invasion, and metastasis. It may participate in ovarian cancer progression by binding to the extracellular matrix and activating pathways involved in cell adhesion, invasion, and migration, including PI3K/Akt, MAPK, and Wnt/β-catenin signaling pathways.

Pancreatic Cancer

MUC16 is also overexpressed in pancreatic cancer. It may contribute to pancreatic cancer cell proliferation and invasion by activating signaling pathways such as MAPK and PI3K/Akt.

Breast Cancer

In some breast cancer cases, high MUC16 expression is associated with malignancy and prognosis. MUC16 may participate in breast cancer cell proliferation and survival by binding to the ErbB2, also known as HER2/neu, receptor and activating ErbB2-related signaling pathways.

Colon Cancer

In colon cancer, elevated MUC16 expression has also been observed. Although related studies remain limited, MUC16 may contribute to colon cancer cell growth and invasion by interacting with extracellular matrix molecules and activating pathways such as PI3K/Akt and MAPK.

Fig. 2. Signaling pathway of MUC16 [1].

MUC16 Protein

MUC16 Synonyms

MUC16 is also known by several related names and aliases:

• CA 125
• CA-125
• CA125
• CA125 ovarian cancer antigen
• Cancer antigen 125
• FLJ14303
• MUC 16
• MUC-16
• MUC16_HUMAN
• Mucin 16
• Mucin 16 cell surface associated
• Mucin-16
• Mucin16
• Ovarian cancer related tumor marker CA125
• Ovarian cancer-related tumor marker CA125
• Ovarian carcinoma antigen CA125

Conclusion

MUC16, or CA125, is a structurally complex and biologically important mucin with major relevance in ovarian cancer research. Its large extracellular domain, extensive glycosylation, tandem repeat regions, SEA modules, and intracellular signaling-associated motifs allow it to participate in epithelial biology, tumor progression, biomarker release, and therapeutic targeting.

In ovarian cancer, MUC16 remains a key molecule because it bridges clinical detection, tumor biology, and emerging treatment strategies. Continued research into MUC16-targeted antibodies, molecular probes, biosensors, CAR-T cell therapies, and combination approaches may help improve diagnostic precision and therapeutic outcomes for patients with MUC16-positive tumors.

References

1. Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 2014 Oct;28(10):4183-99. doi: 10.1096/fj.14-257352. PMID: 25002120.
2. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16. Gene. 2006 May 24;373:28-34. doi: 10.1016/j.gene.2005.12.021. PMID: 16500040.
3. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK. Functions of MUC16 in corneal epithelial cells. Investig Ophthalmol Vis Sci. 2007;48:4509-4518.
4. Akita K, Tanaka M, Tanida S, Mori Y, Toda M, Nakada H. CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. Eur J Cell Biol. 2013;92:257-263.
5. Zhu X, Cai H, Zhao L, Ning L, Lang J. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017 Aug 4;8(38):64607-64621. doi: 10.18632/oncotarget.19929. PMID: 28969098; PMCID: PMC5610030.
6. de Bruijn HW, van Beeck Calkoen-Carpay T, Jager S, Duk JM, Aalders JG, Fleuren GJ. The tumor marker CA 125 is a common constituent of normal cervical mucus. Am J Obstet Gynecol. 1986 May;154(5):1088-91. doi: 10.1016/0002-9378(86)90757-x. PMID: 2422937.
7. Hanisch FG, Uhlenbruck G, Dienst C, Stottrop M, Hippauf E. CA 125 and CA 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk. Eur J Biochem. 1985 Jun 3;149(2):323-30. doi: 10.1111/j.1432-1033.1985.tb08929.x. PMID: 3922759.
8. Zhang H, Yang Y, Wang Y, Gao X, Wang W, Liu H, He H, Liang Y, Pan K, Wu H, Shi J, Xue H, Liang L, Cai Z, Fan Y, Zhang Y. Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification. J Ovarian Res. 2015 Mar 28;8:19. doi: 10.1186/s13048-015-0132-8. PMID: 25886959; PMCID: PMC4383191.
9. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000 Dec;75(4):264-5. doi: 10.1002/1096-9098(200012)75:4<264::aid-jso7>3.0.co;2-q. PMID: 11135268.
10. Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS. MUC16/CA125: tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129. PMID: 24886523; PMCID: PMC4046138.
11. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. PMID: 23478059; PMCID: PMC5795662.